OccuLogix buys into glaucoma treatment technology
This article was originally published in Clinica
OccuLogix has definitively agreed to acquire Solx, a company focused on glaucoma treatment, in a move to diversify its product portfolio into other areas of age-related ophthalmic diseases.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.